# PT-141 Dosage in the Research and the Label (Bremelanotide) > PT-141 dosage as a reported finding: the approved bremelanotide dose is 1.75 mg subcutaneous as needed, max one per 24 h and eight per month. No human dosing recommendation. The approved dose stated flatly as what the label specifies — never a protocol for any reader. One indication, one route, firm limits. ## The short version Here is the PT-141 dosage that exists in the record. The label specifies 1.75 mg given subcutaneously (just under the skin), as needed, for premenopausal women with HSDD (low sexual desire that causes real distress) [11]. The limits are firm: no more than one dose per 24 hours and no more than eight per month [11]. That is reported here as a label finding, not as instructions — this site recommends no dose to anyone. The approved product is a prefilled single-dose injector, not a powder you mix. Material sold as "research chemical" is a laboratory material, not the approved drug [11]. ## The approved dose in premenopausal women with HSDD The approved PT-141 dosage for women is precise. The US prescribing information for bremelanotide specifies 1.75 mg subcutaneous, as needed, at least 45 minutes before anticipated sexual activity, in premenopausal women with acquired, generalized HSDD [11]. The frequency cap is no more than one dose per 24 hours and no more than eight doses per month [11]. Every part of that sentence is load-bearing. The amount is fixed at 1.75 mg — there is no titration schedule, no working up to a higher dose. The timing is as-needed and ahead of activity, not on a daily clock. And the monthly cap of eight exists for a pharmacological reason: the same MC4R the drug uses for desire also sits in appetite circuits, and higher-frequency exposure is where the appetite, blood-pressure, and pigment effects become most relevant [11][12]. This is the only approved dosing, and only for that one population. It is stated here as a documented label finding. No part of this is a recommendation, and nothing here should be read as guidance to self-administer. Dose-finding preceded the label. Phase 2 subcutaneous work in women evaluated 0.75, 1.25, and 1.75 mg before 1.75 mg was carried into the RECONNECT Phase 3 program, where it met both coprimary endpoints [3]. ## Subcutaneous injection as the approved route Subcutaneous injection is the approved route. The approved product is delivered as a subcutaneous (just under the skin) injection in the abdomen or thigh [11]. Two other routes appear in the research history: intranasal, used in early development and discontinued for pharmacokinetic variability, and intravenous, used in early pharmacology [6][7]. The shift to subcutaneous was deliberate. The intranasal formulation showed an erectile effect in early male studies but absorbed unpredictably, and that variability is the reason it was dropped [6]. Subcutaneous PK/PD work in men and women characterized the more consistent injected route and supported carrying it into later development — the route that ultimately reached approval [7][11]. So the approved delivery is not an arbitrary choice; it is the formulation that behaved reliably enough to study at scale. ## Doses in the broader research record Beyond the approved indication, the research used different doses for different questions — none of them approved use. Early intranasal work in men with ED escalated to roughly 7-20 mg, with a statistically significant erectile response above 7 mg [6]. A Phase 1 metabolic protocol in women administered subcutaneous doses up to 2.5 mg, up to three times daily for 15 days — a research protocol only, not a clinical regimen [12]. These higher and more frequent exposures are exactly where the appetite, blood-pressure, and pigment effects become most relevant, which is why frequency is capped in the approved label [11][12]. Reported as findings; recommended to no one. ## Reconstitution and handling There is nothing to reconstitute in the approved product. Bremelanotide is supplied as a prefilled, single-dose subcutaneous autoinjector — not a lyophilized powder that a user mixes [11]. Any reconstitution discussion applies only to research-chemical material, which is a laboratory-handling matter outside the approved drug and outside this site's scope [11]. The practical line is simple: the approved medicine is ready-to-use and prescription-only; "research chemical" powder is an unregulated laboratory material with no verified identity, purity, or concentration [11]. The two are not interchangeable, and this site does not bridge them. ## Why no dose is recommended here This page reports doses; it does not prescribe them. Every figure above — the 1.75 mg label dose, the Phase 2 dose-finding range, the higher experimental exposures — is presented as a documented study or label finding, attributed to a source [3][6][11][12]. None of it is guidance for a reader to act on. The reasoning is built into the pharmacology. PT-141 carries a transient blood-pressure rise that contraindicates it in cardiovascular disease, a nausea rate near 40% over long-term use, and pigment effects that accumulate with frequency [4][9][11][12]. Those are exactly the kinds of effects that make self-directed dosing a clinical question, not an editorial one. Read the full [PT-141 side effects](/side-effects) record for that picture; for anything about personal use, a qualified clinician is the right source, not this site. --- A cold reading of the bremelanotide record — the trial numbers, the label warnings, and the field reports walled off as unverified; no clinic in the dark behind it, and nothing here dispensed, priced, or sold.